Advanced in Sertoli-Leydig Cell Tumor

Dr. Lauren J. Oshry

Oncology | Hematology | Hematology Oncology
10451 Nw 117th Ave, Suite 200, 
Medley, FL 
Accepting New Patients
Advanced in Sertoli-Leydig Cell Tumor
10451 Nw 117th Ave, Suite 200, 
Medley, FL 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Lauren Oshry is an Oncologist and a Hematologist in Medley, Florida. Dr. Oshry is rated as an Advanced provider by MediFind in the treatment of Sertoli-Leydig Cell Tumor. Her top areas of expertise are Breast Cancer, Paget Disease of the Breast, Ovarian Carcinosarcoma, and Ovarian Cancer. Dr. Oshry is currently accepting new patients.

Her clinical research consists of co-authoring 12 peer reviewed articles and participating in 3 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Oncology
Hematology
Hematology Oncology
Licenses
Internal Medicine in MA
Hospital Affiliations
Boston Medical Center
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
BMC HealthNet
  • HMO
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
Cigna
  • EPO
  • HMO
  • PPO
Commonwealth Care Alliance
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
Managed Medicaid
  • OTHER MANAGED MEDICAID
Mass General Brigham Health Plan
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Tufts
  • HMO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 7 Less Insurance Carriers -

Locations

10451 Nw 117th Ave, Suite 200, Medley, FL 33178

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

3 Clinical Trials

A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With >/= 1 CM Residual Invasive Cancer or Positive Lymph Nodes (ypN1mi, ypN1-3) After Neoadjuvant Chemotherapy
A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With >/= 1 CM Residual Invasive Cancer or Positive Lymph Nodes (ypN1mi, ypN1-3) After Neoadjuvant Chemotherapy
Enrollment Status: Active_not_recruiting
Publish Date: October 09, 2025
Intervention Type: Other, Radiation, Procedure, Biological
Study Drug: Pembrolizumab
Study Phase: Phase 3
Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women with Early Breast Cancer
Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women with Early Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: January 13, 2025
Intervention Type: Other
Study Phase: Phase 3
Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients With High-Risk, Hormone Receptor-Positive and HER2/Neu Negative Breast Cancer
Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients With High-Risk, Hormone Receptor-Positive and HER2/Neu Negative Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: December 27, 2024
Intervention Type: Drug, Other
Study Drugs: Anastrozole, Everolimus, Exemestane, Goserelin Acetate, Letrozole, Leuprolide Acetate, Tamoxifen Citrate
Study Phase: Phase 3
View 2 Less Clinical Trials

12 Total Publications

A Multidisciplinary Breast Cancer Clinic Improves Time to Treatment at an Urban, Safety Net Hospital.
A Multidisciplinary Breast Cancer Clinic Improves Time to Treatment at an Urban, Safety Net Hospital.
Journal: Annals of surgical oncology
Published: May 01, 2025
Similar Doctors
Distinguished in Sertoli-Leydig Cell Tumor
Dr. Fernando O. Recio
Hematology Oncology | Oncology
Distinguished in Sertoli-Leydig Cell Tumor
Dr. Fernando O. Recio
Hematology Oncology | Oncology

South Florida Center For Gynecologic Oncology P A

6200 N Federal Hwy, 
Boca Raton, FL 
 (41.9 miles away)
561-997-8991
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Fernando Recio is a Hematologist Oncology specialist and an Oncologist in Boca Raton, Florida. Dr. Recio is rated as a Distinguished provider by MediFind in the treatment of Sertoli-Leydig Cell Tumor. His top areas of expertise are Endometrial Cancer, Malignant Mixed Mullerian Tumor, Ovarian Cancer, Vulvectomy, and Hernia Surgery. Dr. Recio is currently accepting new patients.

Advanced in Sertoli-Leydig Cell Tumor
Dr. Zdenka E. Segota
Hematology Oncology | Hematology | Oncology
Advanced in Sertoli-Leydig Cell Tumor
Dr. Zdenka E. Segota
Hematology Oncology | Hematology | Oncology

Brrh Oncology, LLC

701 Northwest 13th St, 2nd Floor, 
Boca Raton, FL 
 (38.6 miles away)
561-955-6400
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Zdenka Segota is a Hematologist Oncology specialist and a Hematologist in Boca Raton, Florida. Dr. Segota is rated as a Distinguished provider by MediFind in the treatment of Sertoli-Leydig Cell Tumor. Her top areas of expertise are Inflammatory Breast Cancer, Breast Cancer, Paget Disease of the Breast, and Angiosarcoma. Dr. Segota is currently accepting new patients.

Brian M. Slomovitz
Distinguished in Sertoli-Leydig Cell Tumor
Dr. Brian M. Slomovitz
Gynecologic Oncology | Oncology | Obstetrics and Gynecology
Distinguished in Sertoli-Leydig Cell Tumor
Dr. Brian M. Slomovitz
Gynecologic Oncology | Oncology | Obstetrics and Gynecology

Physician Practices Of Msmc LLC

4306 Alton Rd, Fl 3, 
Miami Beach, FL 
 (15.8 miles away)
305-535-3310
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Brian Slomovitz is a Gynecologic Oncologist and an Oncologist in Miami Beach, Florida. Dr. Slomovitz is rated as an Elite provider by MediFind in the treatment of Sertoli-Leydig Cell Tumor. His top areas of expertise are Endometrial Cancer, Ovarian Cancer, Cervical Cancer, Hysterectomy, and Lymphadenectomy. Dr. Slomovitz is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Oshry's expertise for a condition
ConditionClose
    View All 9 Advanced Conditions
    View All 19 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile